SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: carlodb1978, mecosmo2, Chillin up north
Search This Board: 
Last Post: 3/23/2017 1:03:16 PM - Followers: 190 - Board type: Free - Posts Today: 7

Apricus Biosciences, Inc. (APRI)





Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:



NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.

The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.


Share Structure:
Outstanding Shares

Authorized Shares

Investor Relations:
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933




All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


Image result for vitaros                                                  

Image result for vitaros

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
APRI News: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results 03/13/2017 04:19:43 PM
APRI News: Current Report Filing (8-k) 03/13/2017 04:19:34 PM
APRI News: Annual Report (10-k) 03/13/2017 04:19:33 PM
APRI News: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results 03/13/2017 04:13:11 PM
APRI News: Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call 03/09/2017 07:00:29 AM
#27168   List of NASDAQ noncompliant companies. Companies are removed OldtimeramI 03/23/17 01:03:16 PM
#27167   They r following the instruction of fda b carlodb1978 03/23/17 11:48:15 AM
#27161   Trust me, I am not defending Apricus, but casinokid11211 03/22/17 08:27:22 PM
#27159   My basic thought is: why not do everything OldtimeramI 03/22/17 12:43:20 PM
#27158   Questions answered on 7 day device, from Matt beck: eicoman 03/22/17 12:23:48 PM
#27157   Just before the end of this short video Bryce Harper 03/22/17 11:58:52 AM
#27156   Thanks. I'm not in this stock and don't plan OldtimeramI 03/22/17 11:13:40 AM
#27155   Here is the Vitaros product leaflet that Ferring OldtimeramI 03/22/17 10:27:31 AM
#27154   Instructions for Vitaros . . . mecosmo2 03/22/17 07:41:31 AM
#27153   On the "Hope for the Best and Plan Bryce Harper 03/21/17 09:02:24 PM
#27152   Hello Longs. On and off, been scanning growtheport 03/21/17 08:37:51 PM
#27150   Fine. Let the cards fall as they may. OldtimeramI 03/20/17 09:44:12 AM
#27149   I don't need a lecture on risk at eicoman 03/20/17 08:01:39 AM
#27148   Eicoman Your response while well intended - is a OldtimeramI 03/20/17 03:34:40 AM
#27147   From the most recent PR - Apricus anticipates eicoman 03/19/17 12:41:02 PM
#27146   All bickering aside , 100% agree with that Aprilov 03/18/17 12:48:16 PM
#27145   If Apricus has an improved formulation to OldtimeramI 03/18/17 12:47:41 PM
#27144   Well Mean Gene. Overall I would agree with OldtimeramI 03/18/17 11:48:17 AM
#27143   Bottom line, If the product sold in Europe casinokid11211 03/18/17 08:02:18 AM
#27142   I know that management seems to be in mean gene 03/17/17 08:24:44 PM
#27141   Ouch. Good points! OldtimeramI 03/17/17 04:16:22 PM
#27139   And when they have talked about upcoming launches Bryce Harper 03/17/17 03:55:52 PM
#27138   Isn't it true that the FDA must act Bryce Harper 03/17/17 03:42:32 PM
#27137   Hi. Can you tell more about this "Then they PuuliTuku 03/17/17 03:39:36 PM
#27136   They even admit under Risk Factors in their Bryce Harper 03/17/17 03:30:43 PM
#27135   I agree with sci101 and Aprilov - good eicoman 03/17/17 03:23:34 PM
#27134   These small changes typically only need to be sci101 03/17/17 03:10:13 PM
#27132   I am wondering how Apricus can submit the Bryce Harper 03/17/17 02:30:34 PM
#27130   The formulation is the same (in fact it sci101 03/17/17 01:03:55 PM
#27129   Bryce The NDS was submitted to Health Canada back OldtimeramI 03/17/17 01:02:59 PM
#27124   Eicoman can verify this !!!! Old news and OldtimeramI 03/17/17 12:40:50 PM
#27123   Eicoman can verify this !!!! Old news and Aprilov 03/17/17 12:09:37 PM
#27122   The formulation in Canada was identical to European Aprilov 03/17/17 12:04:39 PM
#27121   <It was wasn't a Canada requirement it was Bryce Harper 03/17/17 12:02:19 PM
#27120   It was wasn't a Canada requirement it was Aprilov 03/16/17 10:18:42 PM
#27119   What are the chances that the FDA will Bryce Harper 03/16/17 10:14:56 PM
#27118   Pascoe had 1.6 mill in stock, option's and casinokid11211 03/16/17 06:28:46 AM
#27117   I'm hoping to go lower PPS.. I am OldtimeramI 03/15/17 12:27:35 PM
#27116   I'm hoping to go lower PPS.. I am Aprilov 03/15/17 11:44:28 AM
#27115   I agree twp, they sold off all other eicoman 03/15/17 10:41:02 AM
#27114   good points carlo eicoman 03/15/17 10:38:13 AM
#27113   Pascoe has the full interest in keeping a carlodb1978 03/15/17 08:48:37 AM
#27112   I feel this is a binary play as twpoker 03/15/17 08:01:01 AM
#27111   Don't let Pascoe fool you, the last thing casinokid11211 03/15/17 05:31:43 AM
#27110   Good luck to you growthreport... Aprilov 03/14/17 06:37:34 PM
#27109   Nobody here needs your convoluted numbers ... We OldtimeramI 03/14/17 05:55:45 PM
#27108   I'd rather have Casino at least we know Aprilov 03/14/17 05:05:38 PM
#27107   You got the wrong guy pal !!! I Aprilov 03/14/17 05:04:10 PM
#27106   Pascoe is plenty of shares at 1.2 Not carlodb1978 03/14/17 04:59:19 PM
#27105   I heard Pascoe is on his way out. casinokid11211 03/14/17 04:53:21 PM